Faster Target Discovery Position Resonant as a fast, high value partner for pharma and biotech teams seeking antibodies against difficult targets, offering joint development or sponsored discovery programs to shorten timelines.

Investor Signals Leverage investor interest and venture funding as a credibility signal to prospective customers and strategic partners, offering collaboration models aligned with growth programs.

Lean Partnership Model With a small team, emphasize streamlined, scalable CRO partnerships and fee for service engagements to access rapid antibody generation without expanding internal headcount.

Untapped Target Focus Differentiate by focusing on targets missed by conventional technologies, pitching as a route to novel therapeutics and first in class assets for early stage programs.

Flexible Commercialization Offer flexible commercial models such as platform licensing or exclusive collaboration to enable customers to integrate Resonant's antibodies discovery into their pipelines.